← All trials
NCT06055712
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 11, 2023
- Primary completion
- Sep 30, 2033
- Completion date
- Jan 31, 2034
- First posted
- Sep 28, 2023
- Last posted
- Oct 4, 2023
- Enrollment
- 800
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- St. Louis UniversityLead sponsor
- St. Louis UniversityOverall official - principal investigator
- St. Louis UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.